Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A2 level in experimental stroke

Journal of Neurotrauma

Volumn 26, Issue 12, 2009, Pages 2355-2364

  Kobayashi, Tomonori ^a   Kawamata, Takakazu ^a   Shibata, Noriyuki ^a   Okada, Yoshikazu ^a   Kobayashi, Makio ^a   Hori, Tomokatsu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor type 1 blocker; Cerebral infarction; Cerebral ischemia; Immunoblotting; Immunohistochemistry; Middle cerebral artery occlusion model; Phospholipase A2

Indexed keywords

CYTOSOLIC PHOSPHOLIPASE A2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; CONTROLLED STUDY; CYTOSOL; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME LOCALIZATION; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; STROKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; BRAIN; BRAIN INFARCTION; BRAIN ISCHEMIA; CYTOPROTECTION; CYTOSOL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MOTOR CORTEX; NEURONS; PHOSPHOLIPASES A2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; STROKE;

EID: 75449094099     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.2009.0965     Document Type: Article

References (38)

1. Adibhatla, R.M., and Hatcher, J.F. (2006). Phopholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic. Biol. Med. 40, 376-387.
2. Bederson, J., Pitts, L.H., Germano, S.M., Nishimura, M.C., Davis, R.L., and Bartkowski, H.M. (1986b). Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17, 1304-1308.
3. Bederson, J.B., Pitts, L.H., Tsuji, M., Nishimura, M.C., Davis, R.L., and Bartkowski, H.M. (1986a). Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17, 472-476.
4. Benson, S.C., Pershadsingh, H.A., Ho, C.I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M.A., and Kurtz, T.W. (2004). Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPARgmodulating activity. Hypertension 43, 993-1002.
5. Bernardo, A., and Minghetti, L. (2006). PPAR-g agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Design 12, 93-109.
6. Bonventre, J.V., Huang, Z., Taheri, M.R., O'Leary, E., Li, E., Moskowitz, M.A., and Sapirstein, A. (1997). Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390, 622-625.
7. Chung, O., Stoll, M., and Unger, T. (1996). Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press Suppl. 2, 47-52.
8. Coulon, L., Caizada, C., Moulin, P., Véricel, E., and Lagarde, M. (2003). Activation of p38 mitogen-activated protein kinase=cytosolic phospholipase A2 cascade in hydroxyl peroxide-stressed platelets. Free Radic. Biol. Med. 35, 616-625.
9. De Ryck, M., Van Reempts, J., Duytschaever, H., Van Deuren, B., and Clincke, G. (1992). Neocortical localization of tactile= proprioceptive limb placing reactions in the rat. Brain Res. 573, 44-60.
10. Dronadula, N., Liu, Z., Wang, C., Cao, H., and Rao, G.N. (2005). STAT3-dependent cytosolic phospholipase A2 expression is required for thrombin-induced vascular smooth muscle cell moiety. J. Biol. Chem. 280, 3112-3120.
11. Hamai, M., Iwai, M., Ide, A., Tomochika, H., Tomono, Y., Mogi, M., and Horiuchi, M. (2006). Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 51, 822-828.
12. Hunyady, L., and Catt, K.J. (2006). Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 20, 953-970.
13. Kawamata, T., Alexis, N.E., Dietrich, W.D., and Finklestein, S.P. (1996). Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J. Cereb. Blood Flow Metab. 16, 542-547.
14. Kawamata, T., Dietrich, W.D., Schallert, T., Gotts, J.E., Cocke, R.R., Benowitz, L.I., and Finklestein, S.P. (1997). Intracisternal basic fibroblast growth factor enhances function recovery and up-regulates the expansion of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc. Natl. Acad. Sci. USA 94, 8179-8184.
15. Kawamata, T., Ren, J., Cha, J.H., and Finklestein, S.P. (1999). Intracisternal antisense oligonucleotide to growth associated protein-43 blocks the recovery-promoting effects of basic fibroblast growth factor after focal stroke. Exp. Neurol. 158, 89-96.
16. Kobayashi, T., Kawamata, T., Mitsuyama, T., and Hori, T. (2007). Modified permanent middle cerebral artery occlusion rat model aiming to reduce variability in infarct size. Neurol. Res. 29, 884-887.
17. Kozak, A., Ergul, A., El-Remessy, A.B., Johnson, M.H., Machado, L.S., Elewa, H.F., Abdelsaid, M., Wiley, D.C., and Fagan, S.C. (2009). Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke 40, 1870-1876.
18. Kozak, W., Kozak, A., Johnson, M.H., Elewa, H.F., and Fagan, S.C. (2008). Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J. Pharmacol. Exp. Ther. 326, 773-782.
19. Kurtz, T.W. (2008). Beyond the classic angiotensin-receptorblocker profile. Nat. Clin. Pract. Cardiovasc. Med. 5 Suppl 1, S19-S26.
20. Lang-Rollin, I.C.J., Rideout, H.J., Noticewala, M., and Stefanis, L. (2003). Mechanisms of caspase-independent neuronal death: energy depletion and free radical generation. J. Neurosci. 23, 11015-11025.
21. Lazarewicz, J.W., Wroblewski, J.T., and Costa, E. (1990). N-Methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells. J. Neurochem. 55, 1875-1881.
22. Luo, S.F., Lin, W.N., Yang, C.M., Lee, C.W., Liao, C.H., Leu, Y.L., and Hsiao, L.D. (2006). Induction of cytosolic phospholipase A2 by lipopolysaccharide in canine tracheal smooth muscle cells: involvement of MAPKs and NF-kB pathways. Cell Signal 18, 1201-1211.
23. Massicotte, G., Vanderklish, P., Lynch, G., and Bandry, M. (1991). Modulation of DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid=quisqualate receptors by phospholipase A2: a necessary step in long-term potentiation? Proc. Natl. Acad. Sci. USA 88, 1893-1897.
24. Miller, B., Sarantis, M., Traynelis, S.F., and Attwell, D. (1992). Potentiation of NMDA receptor currents by arachidonic acid. Nature 355, 722-725.
25. Mitsuyama, T., Kawamata, T., Yamane, F., Awaya, A., and Hori, T. (2002). Role of a synthetic pyrimidine compound, MS-818, in reduction of infarct size and amelioration of sensorimotor dysfunction following permanent focal cerebral ischemia in rats. J. Neurosurg. 96, 1072-1076.
26. Nanda, B.L., Nataraju, A., Rajesh, R., Rangappa, K.S., Shekar, M.A., and Vishwanath, B.S. (2007). PLA2 mediated arachidonate free radicals: PLA2 inhibition and neutralization of free radicals by anti-oxidants--a new role of anti-inflammatory molecules. Curr. Top. Med. Chem. 7, 765-777.
27. Saavedra, J.M. (2005). Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol. Neurobiol. 25, 485-512.
28. Sapan, C.V., Lundblad, R.L., and Price, N.C. (1999). Colorimetric protein assay techniques. Biotechnol. Appl. Biochem. 29, 99-108.
29. Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J., Zidek, W., Dominiak, P., and Diener, H.C.; MOSES Study Group. (2005). Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36, 1218-1226.
30. Stella, N., Tence, M., Glowinski, J., and Premont, J. (1994). Glutamate-evoked release of arachidonic acid from mouse brain astrocytes. J. Neurosci. 14, 568-575.
31. Sun, G.Y., Horrocks, L.A., and Farooqui, A.A. (2007). The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J. Neurochem. 103, 1-16.
32. Sun, G.Y., Xu, J., Jensen, M.D., and Simonyl, A. (2004). Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 45, 205-213.
33. Swanson, R.A., Morton, M.T., Tsao-Wu, G., Savalos, R.A., Davidson, C., and Sharp, F.R. (1990). A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10, 290-293.
34. Tontonoz, P., and Spiegelman, B.M. (2008). Fat and beyond: the diverse biology of PPARg. Annu. Rev. Biochem. 77, 289-312.
35. van Putten, V., Refaat, Z., Dessev, C., Blaine, S., Wick, M., Butterfield, L., Han, S.Y., Heasley, L.E., and Nemenoff, R.A. (2001). Induction of cytosolic phospholipase A2 by oncogene Ras is mediated through the JNK and ERK pathways in rat epithelial cells. J. Biol. Chem. 276, 1226-1232.
36. Wagner, J., Drab, M., Bohlender, J., Amann, K., Wienen, W., and Ganten, D. (1998). Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin. Exp. Hypertens. 20, 205-221.
37. Yusuf, S., Diener, H.C., Sacco, R.L., Cotton, D., Ounpuu, S., Lawton, W.A., Palesch, Y., Martin, R.H., Albers, G.W., Bath, P., Bornstein, N., Chan, B.P.L., Chen, S.T., Cunha, L., Dahlöf, B., De Keyser, J., Donnan, G.A., Estol, C., Gorelick, P., Gu, V., Hermansson, K., Hilbrich, L., Kaste, M., Lu, C., Machnig, T., Pais, P., Roberts, R., Skvortsova, V., Teal, P., Toni, D., Vander-Maelen, C., Voigt, T., Weber, M., and Yoon, B.W.; PRoFESS Study Group. (2008). Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359, 1225-1237.
38. Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., and Culman, J. (2005). The intracerebral application of the PPARgammaligand pioglitazone confers neuroprotection against focal ischemia in the rat brain. Eur. J. Neurosci. 22, 278-282.